COLL Collegium Pharmaceutical, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
17.91
PEG
—
P/B
3.50
P/S
1.39
EV/EBITDA
2.71
DCF Value
$634.78
FCF Yield
29.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
60.7%
Operating Margin
23.8%
Net Margin
9.4%
ROE
26.7%
ROA
4.5%
ROIC
10.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $193.5M | $14.5M | $— |
| Q4 null | $205.4M | $17.0M | $— |
| FY null | $780.6M | $62.9M | $— |
| Q3 null | $209.4M | $31.5M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$58.00
Target (Median)
$58.00
Target Range
$56.00 - $60.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.76
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.